KRAS gets the silencing treatment
Mutations in the KRAS protooncogene drive the growth of some of the most lethal human tumors, including pancreatic and lung cancers. Efforts to pharmacologically inhibit KRAS itself, or components of its well-studied signaling pathway, have been largely unsuccessful. Shankar et al. considered the possibility that KRAS may have additional uncharacterized roles that contribute to tumor development and that may be more susceptible to drug treatment.
Science Daily article
